U.S. Continuous Glucose Monitoring Market Size & Share 2025 - 2034

U.S. Continuous Glucose Monitoring Market Size

The U.S. continuous glucose monitoring market size was estimated at USD 4.9 billion in 2024. The market is expected to grow from USD 5.7 billion in 2025 to USD 22 billion in 2034, growing at a CAGR of 16.2%, according to the latest report published by Global Market Insights Inc.

The market is growing significantly due to the increasing prevalence of diabetes in the U.S., the expansion of over-the-counter continuous glucose monitoring devices, the growth of telehealth and remote patient monitoring, and the growing preference for home-based monitoring.
 

Continuous glucose monitoring involves wearable sensor systems that track glucose levels in real-time, helping to manage diabetes more effectively. It includes sensors, transmitters, and receivers that provide continuous data and alerts. Major companies in the market include Abbott Laboratories, Dexcom, Medtronic, F. Hoffmann-La Roche, and Senseonics. With a focus on innovation, major companies in the continuous glucose monitoring (CGM) market offer advanced systems that provide real-time glucose tracking, wearable sensors, mobile app integration, and data-sharing features for patients and healthcare providers.
 

The market grew from USD 3.4 billion in 2021 to USD 4.3 billion in 2023. The U.S. continuous glucose monitoring (CGM) market is experiencing strong growth, driven by increasing demand for home-based health tracking and the expansion of telehealth and remote patient monitoring. These trends are making CGM technology more accessible and integrated into everyday health routines.
 

The convenience of real-time glucose data, combined with digital platforms that support remote consultations and data sharing, is enhancing patient engagement and enabling proactive management of metabolic health. As CGMs evolve from clinical tools to consumer-friendly wellness devices, their adoption is accelerating across both diabetic and non-diabetic populations, contributing significantly to the market’s expansion.
 

The increasing prevalence of diabetes in the U.S. is a major factor fueling market growth. For instance, according to the American Diabetes Association, approximately 38.4 million people in the U.S., representing 11.6% of the population, were living with diabetes in 2021. Of these, around 2 million had type 1 diabetes, including 304,000 children and adolescents. This growing burden has led to heightened demand for advanced diagnostic technologies, such as CGM, for effective monitoring. Thus, healthcare providers and industry leaders are intensifying their efforts and investments to address this critical public health challenge.
 

Additionally, the U.S. continuous glucose monitoring (CGM) market is experiencing strong growth, driven by the rise of over-the-counter (OTC) CGM devices, which is estimated to reach USD 2.14 billion by 2034. In March 2025, the U.S. Food and Drug Administration (FDA) cleared the first OTC continuous glucose monitor for marketing, the Dexcom Stelo Glucose Biosensor System.
 

This integrated CGM (iCGM) is intended for individuals aged 18 and older, including those without diabetes, and features a discreet, wearable sensor that continuously tracks glucose levels and syncs with a smartphone app. By eliminating the need for prescriptions and fingersticks, such innovations are making glucose monitoring more accessible and appealing to a broader population, further accelerating the market’s expansion into wellness and preventive health.
 

Continuous glucose monitoring (CGM) is a medical technology used to track glucose levels in the body continuously throughout the day and night. Unlike traditional blood glucose monitoring, which requires fingerstick blood samples, CGM systems use a small sensor inserted under the skin to measure interstitial glucose levels in real time.
 

U.S. Continuous Glucose Monitoring Market Trends

• CGMs provide a non-invasive, user-friendly alternative to traditional glucose testing methods, allowing users to continuously track glucose levels without frequent clinic visits or fingersticks.
   
• These devices integrate seamlessly with mobile apps and cloud-based platforms, enabling remote data sharing with healthcare providers, that can monitor patient trends and adjust treatment plans accordingly.
   
• Additionally, this shift toward home-based care is particularly beneficial for individuals with chronic conditions, elderly patients, and those with limited mobility, as it supports early intervention, reduces hospitalizations, and enhances overall health outcomes.
   
• For example, Dexcom’s G7 CGM system allows users to monitor their glucose levels at home and share data remotely with clinicians, making it easier to manage diabetes without in-person appointments. As consumer awareness grows and digital health infrastructure strengthens, home-based CGM solutions are becoming central to personalized, preventive care, driving widespread adoption and market expansion.
   

U.S. Continuous Glucose Monitoring Market Analysis

The U.S. continuous glucose monitoring market was valued at USD 3.4 billion in 2021. The market size reached USD 4.9 billion in 2024, from USD 3.7 billion in 2022.
 

Based on the component, the market is segmented into transmitters, sensors, and receivers. The sensor segment led this market in 2024, accounting for the highest market share because of its non-invasive nature and extended wear duration. This segment was valued at USD 2.5 billion in 2024 and is projected to reach USD 11.3 billion by 2034, growing at a CAGR of 16.4%. This growth is due to the shift toward home-based care and personalized treatment.
 

In comparison, the transmitter segment, valued at USD 2.2 billion in 2024, is expected to grow to USD 9.8 billion by 2034, with a slightly higher CAGR of 16.1%, supported by wireless data transmission and cloud connectivity.
 

• Transmitters play an important role in continuous glucose monitoring (CGM) systems by wirelessly transmitting glucose data from the sensor to receivers, smartphones, or insulin pumps. Typically attached to the sensor, transmitters enable real-time data sharing and alerts, allowing users and healthcare providers to continuously and remotely monitor glucose levels.
   
• In the U.S. market, the transmitter segment is experiencing steady growth, driven by rising demand for connected health solutions and remote patient monitoring. Technological advancements are making transmitters smaller, more energy-efficient, and better integrated with cloud platforms and electronic health records (EHRs).
   
• For instance, Dexcom’s G7 system features an all-in-one sensor-transmitter design that simplifies usage and enhances the user experience by reducing the need for multiple components. Additionally, modern transmitters offer longer battery life, Bluetooth connectivity, and real-time alert capabilities, which are especially valuable for individuals managing diabetes in dynamic environments. Their ability to sync with mobile apps and smartwatches is also attracting tech-savvy users and expanding CGM adoption beyond traditional clinical settings.
   
• Furthermore, as CGM systems continue to evolve toward more seamless and user-friendly designs, transmitters are expected to remain a key driver of market growth, particularly in the U.S., where digital health integration and remote monitoring are rapidly advancing.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the continuous glucose monitoring market is segmented into hospitals, home care settings, diagnostic centres and clinics, and other end users. In 2024, hospitals held a share of 10.1%.
 

• The hospital sector plays a pivotal role in driving the growth of the U.S. continuous glucose monitoring (CGM) market as healthcare systems increasingly adopt data-driven, patient-centered approaches.
   
• CGM technology is being integrated across various hospital service lines, including emergency departments, critical care units, post-surgical recovery wards, and endocrinology consults, where real-time glucose monitoring is essential for managing patients with fluctuating or complex glucose profiles. Unlike traditional fingerstick tests, CGMs provide continuous data that supports timely clinical decision-making and enhances patient safety.
   
• Technological advancements have further accelerated CGM adoption in hospital settings. Modern CGM systems offer improved accuracy, extended sensor life, and seamless integration with hospital information systems, enabling clinicians to monitor glucose trends remotely and respond proactively. These capabilities not only improve workflow efficiency but also contribute to better patient outcomes.
   

U.S. Continuous Glucose Monitoring Market Share

• The top five players, Abbott Laboratories, Dexcom, Medtronic, F. Hoffmann-La Roche, and Senseonics, collectively hold 99.9% of the market share in the U.S. continuous glucose monitoring industry. These players continue to dominate the U.S. market by investing in next-generation technologies.
   
• Dexcom drives innovation in continuous glucose monitoring (CGM) with advanced systems such as Dexcom G7 and Stelo, which provide highly accurate, real-time glucose data for a wide range of users. By introducing over-the-counter availability, Dexcom is expanding access beyond traditional diabetic care, enabling individuals to proactively manage their metabolic health.
   
• To broaden their reach and improve outcomes, leading CGM companies are forming strategic partnerships with insurers, telehealth providers, and wellness platforms. These collaborations support the integration of CGMs into value-based care models, including employer-sponsored wellness programs and pharmacy channels, enhancing affordability and user engagement.
   
• Leading companies are also adopting value-based care models and expanding access through over-the-counter CGM devices, particularly for non-insulin-dependent type 2 diabetes patients. These innovations are supported by mobile apps, AI-powered analytics, and personalized dashboards that enhance user engagement and simplify diabetes management in outpatient and decentralized care settings.
   

U.S. Continuous Glucose Monitoring Market Companies

Few of the prominent players operating in the U.S. continuous glucose monitoring industry include:

• Abbott Laboratories
• A. Menarini Diagnostics
• Dexcom
• F. Hoffmann-La Roche
• Glucovation
• Insulet Corporation
• i-SENS
• Medtronic
• Nemaura Medical
• Senseonics
• Sinocare

• Dexcom

Dexcom leads the U.S. CGM market driven by its cutting-edge G7 sensor and the launch of Stelo, the first FDA-cleared OTC CGM. The G7 offers direct-to-smartwatch connectivity, AI-powered food logging, and extended wear time, while Stelo targets wellness-focused consumers and those with prediabetes.
 

• F. Hoffmann-La Roche

Roche is committed to research and development, continuously advancing its CGM technology. Its focus on innovation has led to the development of cutting-edge products such as the Accu-Chek SmartGuide CGM, enhancing user experience and clinical outcomes.
 

• Medtronic

Medtronic leverages its extensive global presence to strengthen market reach, operating in over 150 countries with a robust distribution network. Its CGM product portfolio includes standalone CGM systems as well as integrated solutions such as CGM devices paired with automated insulin pump systems, offering comprehensive diabetes management.
 

U.S. Continuous Glucose Monitoring Industry News:

• In September 2024, Senseonics Holdings, Inc. announced the U.S. Food and Drug Administration (FDA) approval for its next-generation Eversense 365 CGM system, world’s first one year CGM system. This approval is expected to increase the company’s customer base and its competitiveness in the market.
   

The U.S. continuous glucose monitoring market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 to 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Transmitters
• Sensors
• Receivers

Market, By End Use

• Hospitals
• Home care setting
• Diagnostic centres and clinics
• Other end use